Company / Return on Equity (ROE)
Cyclerion Therapeutics, Inc. Return on Equity (ROE) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-38.8%
FY2025
5-year range
-421.7% / -38.8%
FY2021-FY2025
Trend
+16.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cyclerion Therapeutics, Inc. reports negative total equity of -38.8% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-38.8% in FY2025 with a 5-year CAGR of +87.0%.
Improved from -421.7% to -38.8% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +382.9pp
- 5-Year Change
- +87.0pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 16.7% year-over-year.
- Lowest return on equity (roe) in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -19.82 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -38.8% | +16.7% |
| FY2024 | -46.6% | +88.9% |
| FY2023 | -421.7% | +0.0% |
| FY2022 | -421.7% | -222.5% |
| FY2021 | -130.8% | -3.9% |
| FY2020 | -125.9% | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026